SecBot SecBot
8-K ·Filed Mar 11, 2026

ELUT

ELUTIA INC.
MIXED
Impact 7/10
Horizonmonths Processed8mo ago SEC0001104659-26-026398
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The stock may react positively to the strengthened balance sheet and strategic focus on NXT-41x, but traders should monitor whether declining core revenue can be reversed with the new product launch. The release of $8.0 million in escrow in Q4 2026 provides a future cash milestone.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.15
T+0 close · Mar 11, 2026 · via day close
Latest settled
−13.13%
T+60 · $0.9990
Vs SPY
−23.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $1.15entry
  2. T+1 · 8mo ago −6.09%α −5.49% · $1.08
  3. T+5 · 8mo ago −8.70%α −7.72% · $1.05
  4. T+20 · 7mo ago −1.74%α −3.71% · $1.13
  5. T+60 · 5mo ago −13.13%α −23.83% · $0.9990
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope business to Boston Scientific, which generated a net income of $53.4 million for the year. The company strengthened its balance sheet, repaid $26.9 million in debt, and now holds $44.4 million in cash and escrow. It also advanced its NXT-41x development program and initiated a strategic review of its SimpliDerm product line to focus on upcoming commercialization.

Key Financial Metrics

Revenue
$12.3M
-15.0% YoY
EPS
$0.87
Gross Margin
53.7%

Key Facts

  • Closed $88 million sale of BioEnvelope business to Boston Scientific in Q4 2025
  • Full-year 2025 net income was $53.4 million (vs. $53.9 million net loss in 2024), driven by the gain on divestiture
  • Full-year 2025 revenue from continuing operations declined 15.2% to $12.3 million (from $14.5 million)
  • Company repaid $26.9 million in debt and ended 2025 with $36.4 million in cash and $8.0 million in escrow
  • NXT-41 regulatory submission made; clearance expected in second half of 2026
  • Initiated strategic process to explore options for SimpliDerm product line

Financial Impact

Revenue from continuing operations declined 15.2% YoY to $12.3 million in 2025, while net income turned positive at $53.4 million due to $88 million gain on divestiture

revenuenet incomecashdebt

Segment Breakdown

SegmentRevenueGrowth
SimpliDerm$9.1M-21.6%
Cardiovascular$3.2M+10.3%

Risk Factors

  • Core revenue (continuing operations) declined significantly in 2025
  • Future performance now heavily dependent on successful launch of NXT-41x
  • Strategic review of SimpliDerm introduces uncertainty around that product line

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-026398
Document: elut-20260303x8k.htm0001104659-26-026398
Document: 0001104659-26-026398-index-headers.html0001104659-26-026398
Document: 0001104659-26-026398-index.html0001104659-26-026398
Document: 0001104659-26-026398.txt0001104659-26-026398

Track record

7 reports on ELUT

Performance horizon
Filters
  1. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
  3. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
  4. Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
  5. Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
  6. May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
  7. Mar 11, 202635w ago 8-K Mixed 7/10 Viewing Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026